Zoetis Inc.

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zoetis Inc. (NYSE: ZTS) resulting from allegations that Zoetis may have issued materially misleading business information to the investing public.

If you purchased Zoetis securities and would like to join the prospective action, please click “Join This Class Action.”

If you purchased Zoetis securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of investigation:

On April 12, 2024, before the market opened, The Wall Street Journal released an article entitled “What Killed Their Pets? Owners Blame Meds, but Vets Aren’t Sure.” This article discussed possible side effects caused by Librela and Solensia, two drugs which are produced by Zoetis, and are respectively used to treat arthritis in dogs and cats. The article also stated “[h]ealth regulators in the U.S. and Europe—which have received thousands of reports of side effects—are conducting reviews” and that “[t]he FDA received more than 3,800 reports of side effects concerning the drugs through the end of last year.”

On this news, Zoetis’ stock price fell $12.75 per share, or 7.8%, to close at $149.98 per share on April 12, 2024.

公司名称: Zoetis Inc.
股票代号: ZTS
集体诉讼期: N/A
法院: N/A


自 2013 年以来,罗森律师事务所每年都是代表投资者成功提起证券集体诉讼的前四大律所之一。仅 2019 年,本律所就为投资者追回 4.38 亿美元资金。


机构股东服务公司按 2017 年证券集体诉讼索赔数量,罗森律师事务所列为第一名。